Toromont Industries Ltd $ 69.24 3.84 (5.87%)
TMTNF News and Headlines - Toromont Industries Ltd
Equity markets continued their path to recovery during the third quarter. Markets were strong through July and August, as economic data improved, and company earnings reports were generally better than expected. However, September lived up to its reputation as the worst month for stock performance, with markets pulling back on concerns of rising COVID-19 cases across many developed countries and uncertainty over US fiscal stimulus.
The US was the top performing developed market, with the S&P 500 Index up 8.9% in US dollars in the quarter. Canadian and International markets also provided strong returns, both up close to 5% in
“Lower rates for longer!” appears to be the new battle cry, as the 180-degree turnabout by many central banks that we wrote about in Q1 has persisted, with numerous banks cutting rates and/or signalling cuts or other expansionary policies to come.
Most notably, the Federal Reserve held the Federal Funds Rate at 2.50% as expected and confirmed the market’s expectation that it is considering rate cuts later this year. In addition, at a presentation during the European Central Bank’s (ECB) annual forum, Mario Draghi signaled that the ECB was prepared to cut interest rates and expand other monetary
Global economic signals presented a mixed picture in the third quarter of 2018. The U.S. economy forged ahead posting 4.2% real GDP growth, China implemented policies to broaden domestic demand, the U.S. and China announced retaliatory tariffs, NAFTA trade talks dragged out (only to be resolved on the last day of the quarter), and the U.K. continued to prepare for Brexit.
One of the most prominent risks during the third quarter was the rise in U.S. interest rates (with rising rates globally being the key valuation risk for portfolios) which, along with central banks reducing stimulus, added to
Global capital markets responded to a series of positive developments during the quarter that suggest we are in the midst of a synchronized global economic recovery. Global economic growth during the third quarter was the strongest since mid-2010, and the composition of this growth is improving with global capital expenditure now expanding at the fastest pace in six years.
Looking ahead, the outlook is further buoyed by the prospect of additional fiscal stimulus in several developed market economies, including the U.S., Japan and Germany. In the U.S. particularly, the prospect of additional fiscal easing in the form of large tax
In the second quarter of 2011, Mawer Canadian Equity Fund (Trades, Portfolio) acquired a stake in Valeant Pharmaceuticals International Inc. (TSX:VRX), a Canadian pharmaceutical company, then sold pieces of the stake in every second and fourth quarter since – a familiar pattern with Mawer's fourth-quarter deals – until selling the stake entirely in the fourth quarter of 2015.
Mawer sold 201,679 shares for an average price of C$111.15 ($84.43 in U.S. currency) per share, which was more than twice what the fund paid for them in 2011. The divestiture had a -3.01% impact on the guru’s portfolio.
|2020-05-01 $ 44.74 (-4.54%)|